Exelixis Cabometyx FDA Approval
This is a news story, published by Yahoo Finance, that relates primarily to Cabometyx news.
Cabometyx news
For more Cabometyx news, you can click here:
more Cabometyx newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Cabometyx. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest sixth FDA approval news, metastatic pancreatic neuroendocrine tumors news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
cabozantinibTipRanks
•Health
Health
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

87% Informative
Exelixis (EXEL) announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx , for the treatment of unresectable, locally advanced or metastatic pancreatic neuroendocrine tumors and extra-pancreatic NET in patients ages 12 or older.
The approval is “certainly positive” for the stock, Citi analyst David Lebowitz tells investors in a research note.
VR Score
83
Informative language
80
Neutral language
79
Article tone
formal
Language
English
Language complexity
74
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
11
Source diversity
2
Affiliate links
no affiliate links
Small business owner?